March 21, 2025

Research Campus M²OLIE for Improved Cancer Treatment

Research Campus M²OLIE for Improved Cancer Treatment

Third funding phase for collaboration between research and industry – BMBF funds five-year project with ten million euros

The goal of the interdisciplinary research campus “Mannheim Molecular Intervention Environment” (M²OLIE) is to provide tailored treatment for cancer patients with oligometastases that is both minimally invasive and efficient. Based at the Mannheim University Hospital, 25 research and industry partners are collaborating under the leadership of the Medical Faculty Mannheim of Heidelberg University. Following a successful evaluation last year, the research campus has received funding for a third five-year phase, amounting to ten million euros, provided by the Federal Ministry of Education and Research (BMBF).

The steering committee of the M2OLIE research campus includes (from left to right) Prof. Dr Stefan Schönberg, Prof. Dr Patrick Maier, Andreas Schneck, Prof. Dr Carmen Wängler, Prof. Dr Katja Patzel-Mattern, Prof. Dr Hans-Jürgen Hennes und Prof. Dr Frank Giordano an. | © FGV-Medienzentrum

“The M²OLIE research campus, as an innovative and interdisciplinary platform for new approaches in cancer treatment, is an important component of the Health + Life Science Alliance Heidelberg Mannheim. With it, we aim to expand health research, strengthen life sciences research, and intensify transfer into the economy and society,” explains Prof. Dr Frauke Melchior, Rector of Heidelberg University. The M²OLIE framework brings together more than 120 experts from medicine, natural sciences, engineering sciences, computer science, and business administration, who pool their expertise to create personalized medical care for cancer patients.

With the initiative “Research Campus – Public-Private Partnership for Innovation”, the BMBF is supporting large-scale and long-term approaches for on-site collaboration between science and industry over a period of up to 15 years. M2OLIE is one of nine partnerships of this kind and is the second research campus to receive a second extension. The industry partners, including large corporations as well as small and medium-sized enterprises, contribute not only expertise but also significant financial resources to the project. More than 14.5 million euros in private funds have been committed for the third funding phase. 

“M²OLIE is a success story and a source of great hope for patients,” emphasizes Prof. Dr Sergij Goerdt, Dean of Medical Faculty Mannheim. “During the second funding phase, around 60 theses – from undergraduate to postdoctoral level – were successfully completed at our faculty as part of the research campus. And the research results have led to around 200 publications,” says the Dean. The faculty’s research groups in pathology, radiochemistry, radiology, radiation therapy, as well as computer-assisted clinical medicine and automation in medicine and biotechnology, are participating in the projects of the third funding phase. More than 40 medical products are in various stages of development as they progress towards market readiness.

The focus of M²OLIE is on improving the treatment of cancer patients with oligometastases, a stage between a locally confined tumor and widespread metastasis. The basis for this is the so-called closed-loop process, the basic procedure of which is currently being evaluated in a clinical study and is set to be completed in the third funding phase with the help of four project modules. These modules can be flexibly combined in highly complex processes and applications, from patient admission to therapy, to enhance efficiency and precision at the diagnostic, therapeutic, and organizational levels, all while adopting a patient-centered approach.

Further Information

Our latest News

discover more
SPT Labtech and Agilent Introduce Automated Target Enrichment Protocols for Genomic Workflows

SPT Labtech and Agilent Introduce Automated Target Enrichment Protocols for Genomic Workflows

Cambridge, UK, 08 October 2025: SPT Labtech, a pioneer in the design and development of laboratory automation and liquid handling solutions, and Agilent Technologies Inc. (“Agilent”), a global leader in analytical and clinical laboratory technologies, today announced the introduction of automated target enrichment protocols on SPT Labtech’s firefly®+ platform. Automating genomic workflows, the optimized Target […]

PHOENIX fördert Forschung: Pharmazie Wissenschaftspreis für Pharmazeutische Technologie verliehen

PHOENIX fördert Forschung: Pharmazie Wissenschaftspreis für Pharmazeutische Technologie verliehen

Herzlichen Glückwunsch an JunProf. Dr. Philipp Uhl von der Universität Heidelberg und sein Team. Für PHOENIX ist das eine ganz besondere Auszeichnung, denn als approbierter Apotheker mit Schwerpunkt in der pharmazeutischen Forschung verbindet Philipp Uhl Praxis und Forschung – genau das, was die pharmazeutische Versorgung von morgen braucht. Die Forschung des Teams könnte die Arzneimitteltherapie verändern: […]

No more problems with reflective surfaces

No more problems with reflective surfaces

Start-up nanoAR receives funding from a federal “exist”-Forschungstransfer grant for its anti-reflective surface technology Most people have been irritated by the reflection of sunlight on their smartphone display or their spectacles. Many solutions are available — but until now none for curved surfaces or situations with a wide range of light incidence angles. Scientists at […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp